cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Merus Nv
1 own
8 watching
Current Price
$16.86
$0.35
(2.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
780.67M
52-Week High
52-Week High
30.81
52-Week Low
52-Week Low
12.03
Average Volume
Average Volume
0.47M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization780.67M
icon52-Week High30.81
icon52-Week Low12.03
iconAverage Volume0.47M
iconDividend Yield--
iconP/E Ratio--
What does the Merus Nv do?
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More
How much money does Merus Nv make?
News & Events about Merus Nv.
Globe Newswire
7days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
Globe Newswire
1month ago
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (NRG1+) cancer have been treated with zenocutuzumab (Zeno) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned for second half of 2023 - Based on the Companys current...
Zolmax
2 months ago
Summit Therapeutics (NASDAQ:SMMT Get Rating) and Merus (NASDAQ:MRUS Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, ...
Globe Newswire
3 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
Market News Video
3 months ago
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two ...
Frequently Asked Questions
Frequently Asked Questions
What is Merus Nv share price today?
plus_minus_icon
Can Indians buy Merus Nv shares?
plus_minus_icon
How can I buy Merus Nv shares from India?
plus_minus_icon
Can Fractional shares of Merus Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Merus Nv stocks?
plus_minus_icon
What is today’s traded volume of Merus Nv?
plus_minus_icon
What is today’s market capitalisation of Merus Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Merus Nv?
plus_minus_icon
What percentage is Merus Nv down from its 52-Week High?
plus_minus_icon
What percentage is Merus Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$16.86
$0.35
(2.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00